Zepbound Cost in New Hampshire 2026: Cash Pay, Insurance, and Compounded Options

What Is Zepbound and Why Does Price Vary by State?

Zepbound (tirzepatide) is the Eli Lilly obesity-indication formulation of the same molecule sold as Mounjaro for type 2 diabetes. The FDA approved Zepbound on November 8, 2023, for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea [1]. It is a once-weekly subcutaneous injection that acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.

Tirzepatide's mechanism sets it apart from single-agonist GLP-1 drugs like semaglutide. The SURMOUNT-1 trial published in the New England Journal of Medicine (N=2,539) showed that participants on 15 mg tirzepatide lost a mean of 20.9% of body weight at 72 weeks, compared with 3.1% on placebo (P<0.001) [2]. The 10 mg dose produced 19.5% loss; the 5 mg dose, 15.0% loss. These figures rank tirzepatide among the most effective pharmacological weight-loss agents studied to date [2].

State-level pricing variation emerges from three factors: pharmacy negotiated rates, state Medicaid formulary decisions, and the presence or absence of licensed compounding pharmacies. New Hampshire's regulatory environment affects each of these independently, which is why a New Hampshire-specific analysis matters.

How the FDA Label Shapes Prescribing in NH

The FDA label defines the approved indications, contraindications, and titration schedule [1]. Prescribers in New Hampshire follow federal labeling regardless of state policy. The standard starting dose is 2.5 mg weekly for four weeks, with 2.5 mg increments every four weeks up to a maximum of 15 mg weekly [1]. Patients who cannot tolerate escalation may remain at a lower maintenance dose.

The Dual-Receptor Advantage in Clinical Terms

Unlike GLP-1-only drugs, tirzepatide's GIP component appears to amplify insulin secretion and may reduce the nausea burden that limits tolerability of pure GLP-1 agonists [3]. A 2023 analysis in JAMA Internal Medicine examining pooled SURMOUNT data found that discontinuation due to adverse events was 4.3% for tirzepatide versus comparable rates for semaglutide in independent trials, though head-to-head data remain limited [4].

Zepbound Cash-Pay Price in New Hampshire in 2026

The manufacturer's list price for Zepbound is $1,059 per month across all dose strengths. Retail pharmacies in New Hampshire, including CVS, Walgreens, and independent chains, price the drug at or near this list price for uninsured or cash-pay customers in 2026.

No major pharmacy benefit manager has driven the New Hampshire retail price below list for cash-pay patients in 2026. GoodRx and similar discount platforms typically return prices between $920 and $1,059 at NH zip codes, with variation depending on whether the pharmacy accepts a given coupon contract [5].

Why the List Price Is Uniform Across NH

Eli Lilly does not offer a publicly available wholesale acquisition cost that differs by state. Pharmacies pay a uniform WAC and pass markups to consumers. New Hampshire has no state drug price transparency law that mandates public reporting of pharmacy acquisition costs, so patients cannot independently audit the margin [6].

Savings Available Without Insurance

The Eli Lilly Zepbound savings card reduces monthly out-of-pocket costs to as low as $25 for eligible commercially insured patients. For patients without any insurance, Lilly's LillyDirect cash-pay program offered Zepbound at $349 to $499 per month through its direct-to-patient channel in late 2024; check LillyDirect for current 2026 rates, as Lilly has adjusted pricing in response to market competition [1].

The table below summarizes the realistic cost tiers a New Hampshire patient is likely to encounter in 2026.

| Scenario | Estimated Monthly Cost | |---|---| | Retail cash-pay (no discount) | $1,059 | | GoodRx or discount card | $920 to $1,059 | | LillyDirect cash-pay channel | $349 to $499 (verify current rate) | | Commercially insured with savings card | As low as $25 | | NH Medicaid | Not covered | | 503A compounded tirzepatide | $150 to $349 (pharmacy-dependent) |

New Hampshire Medicaid Coverage for Zepbound

New Hampshire Medicaid does not cover Zepbound or tirzepatide for obesity in 2026. The exclusion applies to the standard Medicaid fee-for-service program and to NH's managed care Medicaid program, NH Medicaid Care Management.

This is consistent with a broader national pattern. As of 2024, fewer than half of state Medicaid programs covered GLP-1 agonists for obesity, and several states that added coverage did so only under strict prior-authorization rules [7]. New Hampshire has not enacted legislation requiring obesity-drug Medicaid coverage comparable to the federal Treat and Reduce Obesity Act proposals discussed in Congress.

What NH Medicaid Does Cover

New Hampshire Medicaid covers tirzepatide (Mounjaro) for type 2 diabetes with appropriate diagnosis coding. A patient who has both obesity and type 2 diabetes may qualify for Mounjaro coverage under the diabetes indication [8]. This is not a loophole so much as an accurate use of the drug's two FDA-approved indications. Prescribers should document the diabetes diagnosis clearly when submitting prior-authorization requests.

Federal Policy Context

The Centers for Medicare and Medicaid Services issued guidance in 2023 clarifying that states are not required to cover weight-loss drugs under Medicaid [7]. A future federal rule change could force NH Medicaid to add coverage, but no such rule is finalized as of January 2026.

Prior Authorization Odds on Commercial Plans

Even commercially insured NH patients face prior-authorization requirements on most plans. The American Association of Clinical Endocrinology's 2023 obesity guidelines state that "coverage for anti-obesity medications remains inconsistent and often requires documentation of BMI, comorbidities, and failure of lifestyle interventions" [9]. Gathering that documentation before submitting the PA request cuts denial rates.

Commercial Insurance Coverage of Zepbound in New Hampshire

Coverage depends entirely on the specific plan, not the state. New Hampshire residents hold plans from Anthem BCBS NH, Harvard Pilgrim, Ambetter from NH Healthy Families, Cigna, Aetna, and self-insured employer plans. Each has its own formulary.

Anthem BCBS NH placed Zepbound on Tier 3 or Tier 4 of most commercial formularies in 2024 to 2025, with prior authorization required and step-therapy requirements (documentation of failed lifestyle intervention and sometimes a trial of another anti-obesity medication). Harvard Pilgrim's NH plans similarly require PA, with documentation of BMI 30 or greater, or BMI 27 or greater with a qualifying comorbidity matching the FDA label [1].

The Eli Lilly Savings Card: How It Works in NH

Commercially insured patients who are not on a government-funded plan (Medicaid, Medicare Part D, CHIP, or any federal program) may use the Lilly savings card. The card caps monthly out-of-pocket at $25 for the first year, with a 12-month annual maximum that Lilly sets by program year [1]. New Hampshire pharmacies participate in the savings card program the same as pharmacies in any other state. The card does not work for NH Medicaid or Medicare Part D enrollees, per federal anti-kickback statute restrictions [10].

Patients should apply at the Lilly website before filling the first prescription. The card is activated digitally and submitted at the pharmacy counter like a secondary insurance card.

Step Therapy and How to Satisfy It

Many NH commercial plans require step therapy. A typical step-therapy pathway requires documented failure of at least three to six months of lifestyle intervention before approving a GLP-1 drug [9]. Some plans further require a prior trial of an older anti-obesity medication such as phentermine-topiramate or naltrexone-bupropion. Clinicians should document body weight history, dietary counseling attempts, and any prior drug trials in the PA letter.

Compounded Tirzepatide in New Hampshire: Legality and Cost

Licensed 503A compounding pharmacies in New Hampshire may legally compound tirzepatide when a patient has a valid, individualized prescription from a licensed prescriber. The FDA added tirzepatide to the drug shortage list in 2023, which permitted 503A and 503B outsourcing facilities to compound copies of Zepbound and Mounjaro. The FDA removed tirzepatide from the shortage list in December 2024, which triggered a compliance deadline for 503B bulk compounders to cease production. 503A pharmacies serving individual patients with a valid prescription retained a longer wind-down window [11].

Current Legal Status in NH (January 2026)

As of January 2026, 503A pharmacies in New Hampshire may still fill individualized compounded tirzepatide prescriptions, but FDA enforcement posture is evolving. The FDA's December 2024 shortage removal notice stated that 503B outsourcing facilities must stop producing tirzepatide copies, while acknowledging that state-licensed 503A pharmacies serving specific patients occupy a different regulatory space [11]. Patients and prescribers should confirm the current status with the pharmacy's compliance officer before initiating therapy.

503A vs. 503B: What Patients Need to Know

A 503A pharmacy compounds drugs for a specific patient under a prescription. A 503B outsourcing facility may produce larger batches for sale to clinics and physician offices without patient-specific prescriptions [11]. The distinction matters because most online telehealth platforms that ship compounded tirzepatide at scale have used 503B facilities. Those supplies face the tightest FDA scrutiny after the shortage delisting.

Cost of Compounded Tirzepatide in NH

Compounded tirzepatide from a licensed NH 503A pharmacy typically costs $150 to $349 per month depending on dose and pharmacy overhead, compared with $1,059 for brand Zepbound. Some telehealth platforms advertise compounded tirzepatide at $249 per month for standard doses including 2.5 mg and 5 mg vials.

Quality varies. Compounded drugs are not FDA-evaluated for efficacy, safety, or potency equivalence to the brand product [11]. The FDA has issued warnings about compounded GLP-1 preparations with inaccurate labeling and incorrect concentrations [12]. Patients choosing this route should request a certificate of analysis from the pharmacy and confirm the active ingredient is tirzepatide base, not a salt or derivative not authorized under the shortage exemption.

Telehealth Prescribing of Zepbound in New Hampshire

New Hampshire allows telehealth prescribing of controlled and non-controlled prescription drugs, including Zepbound, provided the prescribing clinician holds a valid New Hampshire license or an appropriate interstate compact license, and the clinical encounter meets the standard of care for in-person visits [13]. Zepbound is not a controlled substance, which simplifies telehealth prescribing relative to drugs like phentermine.

What a NH Telehealth Visit Must Include

The New Hampshire Board of Medicine and Board of Nursing require that telehealth encounters include a complete medical history, a medication review, and documentation of BMI or weight-related comorbidity consistent with the FDA label [13]. A prescriber cannot issue a Zepbound prescription based solely on a patient-filled questionnaire without a synchronous video or audio visit in New Hampshire.

Telehealth Platforms Operating in NH

Several national telehealth platforms serve New Hampshire residents for Zepbound and tirzepatide prescribing, including HealthRX, Hims and Hers Health, Ro, and Found. Pricing structures vary: some bundle the prescription with the drug cost, others charge a separate consultation fee. Patients should confirm that the prescribing clinician is licensed in New Hampshire and that the pharmacy fulfilling the prescription is either a licensed NH 503A compounder or a licensed out-of-state pharmacy registered with the NH Board of Pharmacy.

How to Get the Lowest Possible Zepbound Price in New Hampshire

The cheapest verified path for an eligible commercially insured NH patient is brand Zepbound with the Eli Lilly savings card at $25 per month. For uninsured patients, the options rank roughly as follows.

Option 1: LillyDirect Cash-Pay

LillyDirect ships brand Zepbound at a reduced cash price directly to patients, bypassing retail pharmacy markups. The program price was $349 to $499 per month in late 2024 [1]. This maintains access to the FDA-approved, manufacturer-tested product without insurance involvement.

Option 2: Licensed 503A Compounded Tirzepatide

A valid NH prescription sent to a licensed 503A compounding pharmacy can yield tirzepatide at $150 to $349 per month. The tradeoff is that potency, sterility, and bioequivalence are not FDA-verified [11]. Patients must weigh cost savings against that uncertainty.

Option 3: Prior Authorization Appeal

Patients initially denied by their NH commercial insurer should file a formal appeal. Under New Hampshire RSA 420-J:5, insurers must provide an internal appeal process and, if denied again, an external independent review [6]. Appeals succeed when the clinical record documents BMI, comorbidities, and prior non-pharmacological treatment attempts matching guideline criteria [9].

Option 4: Employer Plan Negotiation

Some NH employers have added anti-obesity medication coverage to their self-insured plans after reviewing pharmacy benefit manager data. Employees in large NH companies (e.g., BAE Systems, Dartmouth Health, state government plans) may be able to petition HR for a formulary exception or plan amendment. The Business Group on Health reported in 2024 that 40% of large employers planned to cover GLP-1 drugs for obesity by 2025 [14].

Clinical Expectations: What NH Patients Should Understand Before Starting

Starting Zepbound is a long-term clinical commitment. The SURMOUNT-1 trial ran 72 weeks, and participants who discontinued tirzepatide regained two-thirds of lost weight within one year in the SURMOUNT-4 extension study (N=670) [15]. This pattern matches the recognized biology of obesity as a chronic, relapsing condition requiring sustained treatment [9].

Titration Schedule and Side Effects

The FDA-approved titration begins at 2.5 mg weekly for four weeks, escalating by 2.5 mg every four weeks to the maintenance dose [1]. Most patients reach 5 mg or 10 mg as their maintenance dose; 15 mg is reserved for patients who need additional weight reduction and tolerate lower doses. Gastrointestinal side effects (nausea, diarrhea, constipation) are most common during dose escalation and typically resolve within two to four weeks of reaching a stable dose [2].

Monitoring Recommendations

The American Association of Clinical Endocrinology recommends monitoring fasting glucose, HbA1c, lipids, and kidney function at baseline and at three-month intervals during the first year of GLP-1/GIP therapy [9]. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide, per the FDA black-box warning [1].

Combining Drug Therapy With Behavioral Support

SURMOUNT-1 participants received lifestyle intervention counseling alongside drug therapy [2]. The FDA label specifies Zepbound as an adjunct to a reduced-calorie diet and increased physical activity [1]. NH patients starting the drug through telehealth should ask their prescribing clinician for a referral to a registered dietitian or a structured behavioral weight-management program. Dartmouth-Hitchcock Medical Center in Lebanon, NH, and Catholic Medical Center in Manchester, NH, both offer multidisciplinary weight management programs that can coordinate with telehealth prescribers.